“Takeda Pharmaceutical's dengue vaccine Qdenga has been approved by India's drug regulator, making it the first such vaccine to be cleared in the country, the Japanese drugmaker's India unit said on Monday.
Dengue is a mosquito-borne viral disease and one of the fastest-spreading vector-borne illnesses globally. The World Health Organization reported a record 14.4 million dengue cases and 11,201 deaths worldwide in 2024, including 232,425 cases and 233 deaths in India…
Reported dengue cases in India rose 11-fold in the past two decades, according to Takeda Biopharmaceuticals India.
Qdenga, designed to protect against all four dengue virus serotypes, is indicated for the prevention of dengue in children and adults aged 4 to 60 years, the company said.
In a late-stage trial, the vaccine, approved in 43 countries so far, showed an efficacy of 80.2% against confirmed dengue cases one year after the second dose.
It also showed 90.4% efficacy against dengue-related hospitalizations after 18 months, meeting the secondary end-point of the study, according to the company.”
From Reuters.
